Your session is about to expire
← Back to Search
Ferumoxytol MRI for Coronary Artery Disease
Study Summary
This trial sought to compare the safety of ferumoxytol-enhanced MRI to gadolinium-based MRI in patients with an eGFR <30 mL/min.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My kidney function, measured by eGFR, is above 30.My kidney function is low, with an eGFR under 30.I am between 18 and 85 years old.
- Group 1: Intervention
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What additional research has been carried out on ferumoxytol?
"Currently, there are 17 different ongoing clinical trials studying ferumoxytol. 4 of those trials have progressed to Phase 3 testing. Most of the trials are being conducted in Stanford, but there are 42 different locations where patients can participate."
Is this research project enrolling people who are 20 or older?
"This research project is open to individuals aged 18-85."
Has ferumoxytol received clearance from the FDA?
"Ferumoxytol Phase 3 trial data looks promising, with evidence of efficacy and safety from multiple rounds of testing--giving it a safety score of 3."
Which patients would best be helped by this clinical trial?
"Those who wish to partake in this coronary artery disease study must be aged between 18 and 85. A total of one hundred and eighty-five patients are needed for the trial."
Share this study with friends
Copy Link
Messenger